Anti-CD3 x Anti-EGFR Bispecific Antibody (EGFRBi) Armed Fresh Peripheral Blood Mononuclear Cells therapy(University Of Virginia)

N/A

Report date: 2026/03/19 17:14:56

Base Information

Drug NameAnti-CD3 x Anti-EGFR Bispecific Antibody (EGFRBi) Armed Fresh Peripheral Blood Mononuclear Cells therapy(University Of Virginia)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived +[4]

Mechanisms of ActionAnti-CD3Epidermal growth factor receptor erbB1 antagonists

TargetsT cell surface glycoprotein CD3Epidermal growth factor receptor erbB1

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Virginia

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Virginia

Inactive CompaniesN/A

Active IndicationsPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A